Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lung Cancer Metastatic × Ipilimumab × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 93 Carcinoma, Non-Small-Cell Lung 30 Carcinoma, Renal Cell 21 Prostatic Neoplasms 14 Neoplasm Metastasis 14 Brain Neoplasms 12 Neoplasms 11 Lung Neoplasms 11 Breast Neoplasms 11 Uveal Melanoma 9 Sarcoma 9 Pancreatic Neoplasms 9 Small Cell Lung Carcinoma 7 Urinary Bladder Neoplasms 6 Kidney Neoplasms 6 Carcinoma, Transitional Cell 6 Carcinoma, Hepatocellular 6 Squamous Cell Carcinoma of Head and Neck 5 Skin Neoplasms 5 Ovarian Neoplasms 5 Diabetes Mellitus, Insulin-Dependent, 12 5 Colorectal Neoplasms 5 Uterine Cervical Neoplasms 4 Triple Negative Breast Neoplasms 4 Histiocytoma, Malignant Fibrous 4 Colonic Neoplasms 4 Urogenital Neoplasms 3 Recurrence 3 Rectal Neoplasms 3 Osteosarcoma 3

Interventions

tremelimumab 1 regramostim 1 evolocumab 1 durvalumab 1 Radiotherapy 1 Radiation 1 Nivolumab 1 Ipilimumab 1 Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05144529 2025-04-17

TOP2101

Duke University

Phase 2 Active not recruiting

Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡